Top

Published in:

Open Access 01-09-2012 | Original Article

Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors

Authors: Haruyasu Murakami, Toshihiko Doi, Nobuyuki Yamamoto, Junichiro Watanabe, Narikazu Boku, Nozomu Fuse, Takayuki Yoshino, Atsushi Ohtsu, Satoru Otani, Kazuhiro Shibayama, Takatoshi Takubo, Elwyn Loh

Published in: Cancer Chemotherapy and Pharmacology | Issue 3/2012

Abstract

Purpose

This study was to investigate the safety and tolerability of ganitumab in Japanese patients with advanced solid tumors.

Methods

Patients were enrolled into 1 of 3 dose cohorts (6, 12, or 20 mg/kg) of single-agent ganitumab administered intravenously every 2 weeks. Dose-limiting toxicity (DLT) was assessed for the first 28 days. The primary objectives were to assess the safety, tolerability, and pharmacokinetics (PK) of ganitumab in Japanese patients with advanced solid tumors. An exploratory pharmacodynamic analysis was done to investigate the relationship between exposure and changes in the level of circulating factors in IGF1R pathway (IGFBP-3 and total IGF-1).

Results

Nineteen patients with ECOG performance status 0–1 (6 in cohort 1 and 3, 7 in cohort 2) received at least 1 dose of ganitumab. Median age was 58.0 years. Tumor types included: breast (4), gastric (3), rectal (2), NSCLC (2), thymic (2), and other cancers (6). No DLTs were observed. The most common grade ≥3 adverse events were neutropenia (21 %), leukopenia (16 %) and lymphopenia (11 %). There was a trend of dose-dependency on severity of thrombocytopenia, but not on that of neutropenia. No neutralizing anti-ganitumab antibodies were detected during this study. Dose-linearity on PK of ganitumab was indicated in the dose range. Tumor response was assessed for 19 patients. Stable disease as best response was reported in 7 patients.

Conclusions

Ganitumab up to 20 mg/kg was tolerable in Japanese patients with advanced solid tumors. The safety and PK profiles were similar to those previously observed in non-Japanese patients.

Blume-Jensen P, Hunter T (2001) Oncogenic kinase signaling. Nature 411:355–365PubMedCrossRef

Mauras N, Attie KM, Reiter EO, Saenger P, Baptista J (2000) High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized, multicenter trial. J Clin Endocrinol Metab 85:3653–3660PubMedCrossRef

Sachdev D, Yee D (2007) Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 6:1–12PubMedCrossRef

Macaulay VM (1992) Insulin-like growth factors and cancer. Br J Cancer 65:311–320PubMedCrossRef

Werner H, Le Roith D (1996) The role of the insulin-like growth factor system in human cancer. Adv Cancer Res 68:183–223PubMedCrossRef

Werner H, Le Roith D (2000) New concepts in regulation and function of the insulin-like growth factors: implications for understanding normal growth and neoplasia. Cell Molec Life Sci 57:932–942PubMedCrossRef

Baserga R, Hongo A, Rubini M, Prisco M, Valentinis B (1997) The IGF-I receptor in cell growth, transformation and apoptosis. Biochim Biophys Acta 1332:F105–F126PubMed

Weroha SJ, Haluska P (2008) IGF-1 receptor inhibitors in clinical trials—early lessons. J Mam Gland Biol Neopl 13:471–483CrossRef

Ryan PD, Goss PE (2008) The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer. Oncologist 13:16–24PubMedCrossRef

10.

Beltran PJ, Mitchell P, Chung Y-A et al (2009) AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells. Mol Cancer Ther 8:1095–1105PubMedCrossRef

11.

Tolcher AW, Sarantopoulos J, Patnaik A et al (2009) Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol 27:5800–5807PubMedCrossRef

12.

Himpe E, Degaillier C, Coppens A, Kooijman R (2008) Insulin-like growth factor-1 delays Fas-mediated apoptosis in human neutrophils through the phosphatidylinositol-3 kinase pathway. J Endocrinol 199:69–80PubMedCrossRef

13.

Pollak M, Beamer W, Zhang J-C (1999) Insulin-like growth factors and prostate cancer. Cancer Metastasis Rev 17:383–390CrossRef

14.

Hwa V, Oh Y, Rosenfeld RG (1999) The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev 20:761–787PubMedCrossRef

15.

Chang YS, Gong K, Sun S et al (2002) Clinical significance of insulin-like growth factor-binding protein-3 expression in stage I non-small cell lung cancer. Clin Cancer Res 8:3796–3802PubMed

16.

Chang YS, Wang L, Suh Y-A et al (2004) Mechanisms underlying lack of insulin-like growth factor-binding protein-3 expression in non-small-cell lung cancer. Oncogene 23:6569–6580PubMedCrossRef

17.

McCaffery I, Tudor Y, Deng H et al (2011) Effect of baseline (BL) biomarkers on overall survival (OS) in metastatic pancreatic cancer (mPC) patients (pts) treated with ganitumab (GAN; AMG 479) or placebo (P) in combination with gemcitabine (G). J Clin Oncol 29(suppl):4041

18.

Ikeda M, Okusaka T, Fukutomi A et al (2011) A phase 1b, open-label study to evaluate the safety of ganitumab (AMG 479) in combination with gemcitabine as first-line therapy in patients with metastatic pancreatic cancer. Presented at the 2011 European Multidisciplinary Cancer Congress, September 23–27, Stockholm (Abstr 6587)

19.

Kindler HL, Richards DA, Stephenson J et al (2010) A placebo-controlled, randomized phase II study of conatumumab (C) or AMG 479 (A) or placebo (P) plus gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (mPC). J Clin Oncol 28(suppl):4035

Title: Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors
Authors: Haruyasu Murakami
Toshihiko Doi
Nobuyuki Yamamoto
Junichiro Watanabe
Narikazu Boku
Nozomu Fuse
Takayuki Yoshino
Atsushi Ohtsu
Satoru Otani
Kazuhiro Shibayama
Takatoshi Takubo
Elwyn Loh
Publication date: 01-09-2012
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 3/2012
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-012-1924-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2012

Comparison of dose intensity of vincristine, d-actinomycin, and cyclophosphamide chemotherapy for child and adult rhabdomyosarcoma: a retrospective analysis

Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer

Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer

Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2 signaling pathways

AZ64 inhibits TrkB and enhances the efficacy of chemotherapy and local radiation in neuroblastoma xenografts

Increased expression and function of P-glycoprotein in peripheral blood CD56+ cells is associated with the chemoresistance of non-small-cell lung cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer